Delhi HC blocks Glenmark from making Zita2 min read . Updated: 20 Mar 2015, 11:41 PM IST
Court order on the anti-diabetes drug follows plea by US-based firm on patent infringement
New Delhi: Glenmark Pharmaceuticals Ltd cannot make or sell the anti-diabetes drug sitagliptin, the Delhi high court ordered on Friday after hearing US-based Merck Sharp and Dohme Corp.’s plea on patent infringement.
Select your Category